PolyPeptide Group AG
F:8H0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PolyPeptide Group AG
F:8H0
|
CH |
|
P
|
Perenti Global Ltd
OTC:AUSDF
|
AU |
|
T
|
Takeda Pharmaceutical Co Ltd
OTC:TKPHF
|
JP |
|
Mcphy Energy SA
OTC:MPHYF
|
FR |
|
Absci Corp
NASDAQ:ABSI
|
US |
|
R
|
Repligen Corp
XMUN:RGN
|
US |
|
Pernod Ricard SA
PAR:RI
|
FR |
|
Atlantic Sapphire ASA
OTC:AASZF
|
NO |
|
Definity Financial Corp
TSX:DFY
|
CA |
|
Barnes & Noble Education Inc
NYSE:BNED
|
US |
|
Pagegroup PLC
LSE:PAGE
|
UK |
|
P
|
Pagegroup PLC
F:3MI
|
UK |
|
F
|
Feedback Technology Corp
TPEX:8091
|
TW |
|
B
|
BAWAG Group AG
OTC:BWAGF
|
AT |
Wall St Price Targets
8H0 Price Targets Summary
PolyPeptide Group AG
According to Wall Street analysts, the average 1-year price target for 8H0 is 28.29 EUR with a low forecast of 25.88 EUR and a high forecast of 31.86 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 8H0's stock price target?
Price Target
28.29
EUR
According to Wall Street analysts, the average 1-year price target for 8H0 is 28.29 EUR with a low forecast of 25.88 EUR and a high forecast of 31.86 EUR.
What is the Revenue forecast for PolyPeptide Group AG?
Projected CAGR
17%
Over the last 6 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 5 years is 17%.
What is the Gross Profit forecast for PolyPeptide Group AG?
Projected CAGR
36%
Over the last 6 years, the compound annual growth rate for Gross Profit has been -1%. The projected CAGR for the next 4 years is 36%.
What is the Operating Income forecast for PolyPeptide Group AG?
Projected CAGR
43%
Over the last 6 years, the compound annual growth rate for Operating Income has been -18%. The projected CAGR for the next 8 years is 43%.
